Publicacións en colaboración con investigadores/as de Hôpital Européen Georges-Pompidou (7)

2019

  1. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/ mTOR axis in metastatic pheochromocytoma/ paraganglioma

    Theranostics, Vol. 9, Núm. 17, pp. 4946-4958

  2. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-PronO study): A European network for the study of adrenal tumors retrospective study

    Journal of Clinical Endocrinology and Metabolism, Vol. 104, Núm. 6, pp. 2367-2374

2018

  1. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients

    Genetics in Medicine, Vol. 20, Núm. 12, pp. 1652-1662

2017

  1. The mTORC1 Complex Is Significantly Overactivated in SDHX -Mutated Paragangliomas

    Neuroendocrinology, Vol. 105, Núm. 4, pp. 384-393

2015

  1. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers

    Clinical Cancer Research, Vol. 21, Núm. 13, pp. 3020-3030

  2. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: A multicenter interobserver variation analysis using virtual microscopy: A Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)

    Modern Pathology, Vol. 28, Núm. 6, pp. 807-821

2014

  1. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas

    Human Molecular Genetics, Vol. 23, Núm. 9, pp. 2440-2446